CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-17 | Yu Yong VP, Clinical Trial Operations | Sale | −3,541 | $13.04 | $46K | 102,594 |
| 2023-10-25 | Szalay Aladar 10% owner | Sale | −5,704 | $19.40 | $111K | 1,371,545 |
| 2023-10-24 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion | +5,200 | $6.00 | $31K | 111,335 |
| 2023-10-24 | Yu Yong VP, Clinical Trial Operations | Sale | −5,200 | $19.11 | $99K | 106,135 |
| 2023-10-24 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion · Stock Option (right to buy) | −5,200 | 207,653 | ||
| 2023-10-23 | Szalay Aladar 10% owner | Sale | −49,987 | $19.97 | $998K | 1,377,249 |
| 2023-10-16 | Thomas John Director | Sale | −2,452 | $20.50 | $50K | 473,341 |
| 2023-10-16 | Thomas John Director | Sale | −881 | $21.30 | $19K | 472,460 |
| 2023-10-10 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion | +5,200 | $6.00 | $31K | 111,335 |
| 2023-10-10 | Yu Yong VP, Clinical Trial Operations | Sale | −4,800 | $21.94 | $105K | 106,535 |
| 2023-10-10 | Yu Yong VP, Clinical Trial Operations | Sale | −400 | $22.91 | $9K | 106,135 |
| 2023-10-10 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion · Stock Option (right to buy) | −5,200 | 212,853 | ||
| 2023-10-05 | Szalay Aladar 10% owner | Sale | −13,266 | $24.89 | $330K | 1,428,221 |
| 2023-10-05 | Szalay Aladar 10% owner | Sale | −985 | $25.47 | $25K | 1,427,236 |
| 2023-10-03 | Szalay Aladar 10% owner | Sale | −75,690 | $25.49 | $1.9M | 1,441,487 |
| 2023-10-02 | Jewett Caroline Head of Quality | Grant or award · Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2023-09-28 | Szalay Aladar 10% owner | Sale | −2,289 | $24.12 | $55K | 1,517,177 |
| 2023-09-27 | Szalay Aladar 10% owner | Sale | −11,257 | $24.47 | $275K | 1,519,466 |
| 2023-09-26 | Szalay Aladar 10% owner | Sale | −7,465 | $22.47 | $168K | 1,553,063 |
| 2023-09-26 | Szalay Aladar 10% owner | Sale | −12,740 | $24.03 | $306K | 1,540,323 |
Page 11 of 16 · 315 trades